GBT
AZN icon

Grove Bank & Trust’s AstraZeneca AZN Stock Holding History

Grove Bank & Trust’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.1M Buy
+5,776
New +$1.09M 0.11% 111
2026
Q1 		– Sell
-5,785
Closed -$1.06M – 860
2025
Q4 		$1.06M Buy
5,785
+47
+0.8% +$8.24K 0.12% 109
2025
Q3 		$880K Sell
5,738
-138
-2% -$20.9K 0.1% 123
2025
Q2 		$821K Sell
5,876
-469
-7% -$65.7K 0.1% 123
2025
Q1 		$933K Buy
6,345
+1,023
+19% +$148K 0.12% 110
2024
Q4 		$697K Sell
5,322
-378
-7% -$52.9K 0.1% 128
2024
Q3 		$888K Buy
5,700
+189
+3% +$30.5K 0.13% 102
2024
Q2 		$860K Hold
5,511
– – 0.14% 97
2024
Q1 		$747K Hold
5,511
– – 0.13% 108
2023
Q4 		$742K Sell
5,511
-243
-4% -$31.6K 0.14% 114
2023
Q3 		$779K Buy
5,754
+170
+3% +$23.2K 0.16% 112
2023
Q2 		$799K Sell
5,584
-45
-0.8% -$6.62K 0.16% 107
2023
Q1 		$781K Buy
5,629
+31
+0.6% +$4.17K 0.17% 107
2022
Q4 		$759K Sell
5,598
-102
-2% -$12.8K 0.17% 108
2022
Q3 		$626K Sell
5,700
-265
-4% -$33.6K 0.16% 114
2022
Q2 		$788K Sell
5,965
-7
-0.1% -$918 0.19% 101
2022
Q1 		$792K Hold
5,972
– – 0.16% 117
2021
Q4 		$696K Hold
5,972
– – 0.13% 127
2021
Q3 		$717K Buy
5,972
+6
+0.1% +$698 0.15% 116
2021
Q2 		$714K Sell
5,966
-83
-1% -$9.11K 0.15% 121
2021
Q1 		$601K Sell
6,049
-58
-0.9% -$5.83K 0.14% 127
2020
Q4 		$610K Sell
6,107
-1
-0% -$106 0.16% 117
2020
Q3 		$669K Hold
6,108
– – 0.2% 106
2020
Q2 		$646K Sell
6,108
-236
-4% -$24.4K 0.21% 100
2020
Q1 		$567K Sell
6,344
-149
-2% -$14K 0.22% 96
2019
Q4 		$647K Sell
6,493
-519
-7% -$48.9K 0.19% 109
2019
Q3 		$625K Sell
7,012
-98
-1% -$8.5K 0.2% 111
2019
Q2 		$587K Sell
7,110
-1,563
-18% -$123K 0.21% 103
2019
Q1 		$701K Sell
8,673
-1,488
-15% -$117K 0.27% 91
2018
Q4 		$772K Buy
10,161
+526
+5% +$41.1K 0.36% 68
2018
Q3 		$763K Sell
9,635
-153
-2% -$11.6K 0.31% 79
2018
Q2 		$687K Buy
9,788
+109
+1% +$7.84K 0.29% 82
2018
Q1 		$677K Buy
9,679
+986
+11% +$68.3K 0.3% 85
2017
Q4 		$603K Buy
8,693
+273
+3% +$18.4K 0.26% 91
2017
Q3 		$571K Buy
8,420
+2,547
+43% +$161K 0.28% 88
2017
Q2 		$400K Buy
5,873
+674
+13% +$44K 0.26% 95
2017
Q1 		$324K Buy
5,199
+136
+3% +$7.92K 0.27% 73
2016
Q4 		$277K Buy
5,063
+675
+15% +$38.3K 0.21% 85
2016
Q3 		$288K Buy
4,388
+663
+18% +$43.3K 0.25% 81
2016
Q2 		$225K Hold
3,725
– – 0.2% 83
2016
Q1 		$210K Hold
3,725
– – 0.19% 90
2015
Q4 		$253K Buy
+3,725
New +$244K 0.23% 80

Other funds holding AZN

RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
AAMU
AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $9.71B AUM 37.32% 1-Year Est. Return
MIF
Mediolanum International Funds Dublin 1, Ireland $11.7B AUM 47.18% 1-Year Est. Return
ZIC
ZWJ Investment Counsel Atlanta, Georgia $3.09B AUM 39.43% 1-Year Est. Return
AIM
Achmea Investment Management Zeist, Netherlands $4B AUM 31.99% 1-Year Est. Return

Grove Bank & Trust's AZN Position: Q2 2026 in Review

Grove Bank & Trust opened a new position in AstraZeneca (AZN) in Q2 2026: 5,776 shares worth $1.1M. The stake represents 0.11% of the portfolio and ranks #111 among its holdings. This is a return to the name: Grove Bank & Trust previously reported a position in AZN as recently as Q4 2025.

Grove Bank & Trust first reported a position in AZN in Q4 2015 and has held it in 42 quarters since. 399 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Grove Bank & Trust held 5,776 shares of AstraZeneca worth $1.1M as of Q2 2026.
  • AstraZeneca was a new Grove Bank & Trust position in Q2 2026.
  • AstraZeneca made up 0.11% of Grove Bank & Trust's portfolio in Q2 2026, its #111 holding.
  • Grove Bank & Trust first reported a position in AstraZeneca in Q4 2015 and has held it in 42 quarters since.
  • 399 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Grove Bank & Trust's 13F filing for Q2 2026, filed 7 Jul 2026.